Pharmaceutical Belgium-based VIB, a non-profit research institute in life sciences, and the Center for Drug Design and Discovery (CD3), a technology transfer platform and investment fund, have signed a license and collaboration agreement with Anglo-Swedish pharma major AstraZeneca for the development of novel MALT1 inhibitors as therapeutics in inflammatory and oncological diseases. 31 January 2014